App-Quantinova.ai

Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?

Dafna Gladman - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry

Emmanouil Rampakakis - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Doubleâ€‘Blind, Placebo-Controlled, Dose-Ranging Study

Laure Gossec - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

N/A

bimekizumab

Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort

Orit Schieir - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxyzine

Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity

Zahi Touma - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Prednisone

Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada

Bo Pan - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes

Lianne Gensler - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Non-radiographic axial spondyloarthritis

Certolizumab pegol

Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

Dafna Gladman - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Ustekinumab

Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids

Michele McDermott - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Glucocorticoid

Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

Dafna Gladman - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ankylosing spondylitis

Methotrexate

Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis

Amanda Eudy - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

N/A

Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

Robert B.M. Landewe - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

secukinumab

Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study

Ian Bruce - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Dapirolizumab pegol

Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results

Alan Kivitz - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis

Xavier Chevalier - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Knee osteoarthritis

Hylan G-F20

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

Oliver Distler - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Interstitial lung disease

Nintedanib

Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease

Arkadi Chines - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Chronic kidney disease

Romosozumab

Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study

Janet Pope - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Tasocitinib

Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis

In-Ho Song - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Ankylosing spondylitis

ABT-494

Efficacy and Safety of Upadacitinib Monotherapy in MTX-naÃ¯ve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT-EARLY

Maria Andersson - American College of Rheumatology (ACR) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

ABT-494

Filters

28841 Abstracts